Ganguly, Bishu
Pfizer (United States) · Lyell Immunopharma (United States)
2 papers on CoChat
Most cited papers
- Verified
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
Noel, M., O’Reilly, E. M., Wolpin, B. M., Ryan, D. P., Bullock, A. J., Britten, C. D., Linehan, D. C., Belt, B. A., Gamelin, E. C., Ganguly, B., et al. (2020) · Investigational New Drugs
Pancreatic and Hepatic Oncology ResearchChemokine receptors and signaling
Cited by 199
- Verified
Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease
Martyanov, V., Kim, G.-H. J., Hayes, W., Du, S., Ganguly, B. J., Sy, O., Lee, S. K., Bogatkevich, G. S., Schieven, G. L., Schiopu, E., et al. (2017) · PLOS ONE
Systemic Sclerosis and Related DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Cited by 71
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free